PDCD1 and neoplasm: These findings led to the hypothesis that melanoma cells activate a self-protective response system against the immune attack in the tumor microenvironment and that patients could benefit from the double combination treatment using targeted therapy (or chemotherapy) and anti-PD-1 immunotherapy.